InsiderPulse| Date | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | Mancini Anthony | See Remarks | Sale | 3,120 | $132.41 | $413K | 54.4K | View ↗ | |
| 2026-03-25 | Mancini Anthony | See Remarks | Sale | 37.5K | $95.56 | $3.58M | 54.4K | View ↗ |
No annual data found.
Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026
Erasca Shares Plunge 48% After Trial Patient Death, Patent Dispute Emerges
Revolution’s on a pancreatic cancer winning streak. What comes next for the biotech?
Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial
Erasca: Strong Data Overshadowed By A Patient Death And A Patent Fight
Erasca Stock Sinks 48% in Race for Pancreatic Cancer Miracle Drug. What’s Behind the Sell-Off.
Why Erasca, Up 415% This Year Amid Revolution-Tied Furor, Just Lost Half Its Value
Assessing Revolution Medicines (RVMD) Valuation After Positive RASolute 302 And Zoldonrasib Clinical Updates
SBIO: Leaning Into Drug Discovery And Medical Breakthroughs
Revolution Medicines rival Erasca falls after early-stage trial data for cancer therapy
Summit Therapeutics leads all large-cap healthcare stocks in YoY CapEx growth
Revolution Medicines Trial Updates Spark Fresh Interest In RAS Focused Pipeline